Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study Data from 47,768 cancer survivors and ...
Please provide your email address to receive an email when new articles are posted on . There were no significant differences in HAQ-DI or CHFS score change in patients treated with hydroxychloroquine ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results